Presentation is loading. Please wait.

Presentation is loading. Please wait.

Secondary prevention of a Recurrent ACS; Results from the 2004 & 2006 ACSIS Survey Perl L, Behar S, Schwartz R, Mosseri M Meir Hospital and Sheba Tel Hashomer,

Similar presentations


Presentation on theme: "Secondary prevention of a Recurrent ACS; Results from the 2004 & 2006 ACSIS Survey Perl L, Behar S, Schwartz R, Mosseri M Meir Hospital and Sheba Tel Hashomer,"— Presentation transcript:

1 Secondary prevention of a Recurrent ACS; Results from the 2004 & 2006 ACSIS Survey Perl L, Behar S, Schwartz R, Mosseri M Meir Hospital and Sheba Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University

2 Introduction The preventive effects of cardiovascular drugs after an acute coronary syndrome (ACS) are well established, but little is known concerning the characteristics of a recurrent event, if one should occur. We therefore studied the characteristics of an ACS in patients who present with a recurrent ACS (RACS), and the association with secondary preventive drugs.

3 Methods Data was collected from the 2004 and 2006 ACSIS (Acute Coronary Syndrome Israeli Survey) - a biannual survey on acute myocardial infarction performed in 26 intensive cardiac care units in Israel during a two-month period. In the two surveys, there were 1207 RACS out of 4168 patients over all.

4 Secondary treatment surveyed: ACEi, beta blockers, statins, platelet inhibitors. Data were analysed and was assessed for survival according to secondary treatment rates according to the following variables: Recurrent vs. first ACS, KILLIP and TIMI risk scores, and other variables. Methods 2

5 Patients’ Characteristics KILLIP TIMI FACS Age Female MaleGender % of TotalNumberVariableCategory

6 Results (I)- Treatment Rates

7 Results (II)-‏ Mortality according to number of drugs P=NS

8 Results (III)- ‏1 Year Mortality ????? ?????

9 Results (III)‏ However, when corrected for TIMI scores, there is a trend towards lower mortality in the 3-4 drugs (OR=0.88, CI 0.49-1.61 in the high TIMI score). However, when corrected for TIMI scores, there is a trend towards lower mortality in the 3-4 drugs (OR=0.88, CI 0.49-1.61 in the high TIMI score).

10 Conclusions In general, RACS patients are under treated with secondary preventive drugs prior to admission. Although initial analysis revealed a trend for a higher short term mortality rate in those who were treated with more drugs, there was no change in mortality when adjusted for confounding factors. After a year….????


Download ppt "Secondary prevention of a Recurrent ACS; Results from the 2004 & 2006 ACSIS Survey Perl L, Behar S, Schwartz R, Mosseri M Meir Hospital and Sheba Tel Hashomer,"

Similar presentations


Ads by Google